Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
15/10/2026 17:04
BRIEF-Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care Oct 15 (Reuters) - Sanofi SA SASY.PA:
SANOFI AND PCPA SIGN LETTER OF INTENT FOR DUPIXENT® ACROSS FOUR INDICATIONS IN DERMATOLOGY AND RESPIRATORY CARE
TO SUPPORT PATIENT ACCESS TO DUPIXENT VIA PUBLIC DRUG PLANS IN CANADA
Source text: ID:nCNWr53dFa
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement